Phytohealth Corp

PhytoHealth operates with a strong liquidity position, as evidenced by a current ratio of 27.41, indicating a significant excess of current assets over current liabilities. The company's price-to-book ratio of 1.28 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, implying no premium for intangible assets. The company's cash and equivalents of TWD 60.5 million provide a buffer against short-term obligations, and its long-term debt of TWD 15.7 million is minimal relative to total equity of TWD 1.87 billion. Profitability metrics reveal a challenging operating environment for PhytoHealth. The company reported a net loss of TWD 58.2 million and an operating loss of TWD 174.6 million, resulting in a negative return on equity of -3.11% and a return on assets of -2.47%. These figures fall significantly below the industry median for profitability metrics, indicating underperformance relative to peers. The company's revenue is derived from a mix of product lines, including western medicines, Chinese herbal medicines, cosmetics, Class B drugs, and supplementary food. However, the financial snapshot does not provide a breakdown of revenue by segment or geography, making it difficult to assess concentration risk or geographic exposure. The absence of segmental data limits the ability to evaluate the performance of individual product lines or regions. PhytoHealth's growth trajectory appears constrained, with no specific outlook data provided for the current or next fiscal year. The company's operating cash flow of -TWD 39.7 million and free cash flow of -TWD 67.4 million indicate a cash outflow from operations, which could hinder growth initiatives. The capital expenditure of -TWD 5.87 million suggests limited investment in expansion or modernization. Risk factors for PhytoHealth include the potential for dilution, although the risk is currently assessed as low. The company has no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.01 indicates a conservative capital structure with minimal leverage. However, the negative net income and operating income suggest operational challenges that could affect long-term stability. Recent events and filings do not highlight any significant developments for PhytoHealth. The company's last actual EPS was -TWD 1.00, reflecting the ongoing financial difficulties. Analysts have not provided forward-looking guidance, and there are no notable transcripts or filings that indicate strategic shifts or new product launches.